FTRE
Fortrea Holdings Inc. · Healthcare · Biotechnology
Momentum inputs (comparable managers): holder breadth 0.0% · share flow -9.8% · net new positions 0.0% · formula
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2025
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 155.91K | $3.15M | n/a | n/a |
| Q2 2026 | 103 | +8 | 73.96M | $1.29B | +12 | −6 |
| Q1 2026 | 100 | -4 | 67.95M | $640.51M | +5 | −9 |
| Q4 2025 | 104 | 0 | 71.13M | $1.23B | +1 | −1 |
| Q3 2025 | 18 | 0 | 53.25M | $448.39M | +2 | −2 |
| Q2 2025 | 15 | +1 | 46.90M | $231.21M | +1 | n/a |
| Q1 2025 | 11 | -2 | 16.99M | $128.27M | +1 | −3 |
| Q4 2024 | 13 | +3 | 14.50M | $270.52M | +4 | −1 |
| Q3 2024 | 9 | -2 | 13.45M | $268.92M | n/a | −2 |
| Q2 2024 | 11 | n/a | 13.76M | $321.15M | n/a | n/a |
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | BlackRock ✦ (passive) | 14.19M | -2.9% | $119.48M | 0.0% | ▼ Trim | 2 | SEC ↗ ×12 |
| 2 | The Vanguard Group ✦ (passive) | 8.07M | -7.1% | $67.97M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 3 | Goldman Sachs Group ✦ | 7.98M | n/a | $67.18M | 0.0% | n/c | 1 | SEC ↗ ×2 |
| 4 | State Street Global Advisors ✦ (passive) | 4.07M | -8.2% | $34.28M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 5 | AQR Capital Management ✦ | 3.74M | -42.7% | $31.45M | 0.0% | ▼ Trim | 6 | SEC ↗ ×6 |
| 6 | Fidelity (FMR) ✦ | 3.05M | -0.6% | $25.70M | 0.0% | ▼ Trim | 2 | SEC ↗ ×3 |
| 7 | Morgan Stanley ✦ | 2.81M | n/a | $23.64M | 0.0% | n/c | 1 | SEC ↗ ×13 |
| 8 | Geode Capital Management ✦ (passive) | 2.08M | -4.1% | $17.54M | 0.0% | ▼ Trim | 6 | SEC ↗ ×2 |
| 9 | JPMorgan Chase ✦ | 1.39M | n/a | $11.67M | 0.0% | n/c | 1 | SEC ↗ ×12 |
| 10 | Millennium Management ✦ | 1.35M | -22.3% | $11.39M | 0.0% | ▼ Trim | 4 | SEC ↗ |
| 11 | Renaissance Technologies ✦ | 1.29M | +118.5% | $10.90M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 12 | Two Sigma Investments ✦ | 1.12M | +4.9% | $9.43M | 0.0% | ▲ Add | 3 | SEC ↗ |
| 13 | D. E. Shaw & Co. ✦ | 1.08M | +2.2% | $9.08M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 14 | Citadel Advisors ✦ | 609.41K | +309.1% | $5.13M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 15 | Arrowstreet Capital ✦ | 130.94K | New | $1.10M | 0.0% | New | 1 | SEC ↗ |
| 16 | Point72 Asset Management ✦ | 117.50K | New | $989,349 | 0.0% | New | 1 | SEC ↗ |
| 17 | T. Rowe Price ✦ | 92.47K | +16.8% | $779,000 | 0.0% | ▲ Add | 6 | SEC ↗ |
| 18 | Marshall Wace ✦ | 79.73K | -59.0% | $671,361 | 0.0% | ▼ Trim | 4 | SEC ↗ ×2 |
“Their weight” = the position's share of that manager's reported 13F equity value: the conviction measure. ✦ = curated manager.
New buyers
| Arrowstreet Capital | $1.10M | 0.0% |
| Point72 Asset Management | $989,349 | 0.0% |
Exited
| Starboard Value | $12.33M | was 0.2% |
| Gotham Asset Management | $137,268 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 327 holders, 98.96M shares, $906.93M reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold: shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 3.15K sh · $53,061
Officer · 246 sh · $4,145
Officer · 4.89K sh · $88,985
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology